Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
RANITIDINE HYDROCHLORIDE
Primecrown Ltd.
300 Milligram
Coated Tablets
2003-08-08
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zantac Tablets 300 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains ranitidine 300 mg (as the hydrochloride). _For excipients, see 6.1._ 3 PHARMACEUTICAL FORM Film-coated tablet. White, capsule-shaped, film-coated tablets engraved ‘GX EC3’ on one face and plain on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. Prevention of non-steroidal anti-inflammatory drug associated duodenal ulcers especially in patients with a history of peptic ulcer disease. Post-operative ulcer. Oesophageal reflux disease including long term management of healed oesophagitis. Symptomatic relief in gastro-oesophageal reflux disease. Zollinger-Ellison Syndrome. Prophylaxis of recurrent haemorrhage with bleeding peptic ulcers. Before general anaesthesia in patients at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour. Treatment of other conditions where reduction of gastric acid secretion is likely to be beneficial. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS: Duodenal ulcer, gastric ulcer: The standard dosage regimen is 150 mg twice daily or 300 mg at night. It is not necessary to time the dose in relation to meals. This may be increased to 300mg twice daily without an increased incidence of side effects.Subsequently,a maintenance dose of 150mg at night may be used. Smoking is associated with a higher rate of ulcer relapse, and such patients should be advised to stop smoking. In those who fail to comply with such advice, a dose of 300mg at night provides additional therapeutic benefit over the standard dose. IRISH MEDICINES BOARD ________________________ Pročitajte cijeli dokument